Transposition of Tn5 in Escherichia coli is regulated by two transposon-encoded proteins: transposase (Tnp), promoting transposition preferentially in cis, and the trans-acting inhibitor (Inh). Two separate transposase mutants were isolated that replace glutamate with lysine at position 110 (EKilO) and at position 345 (EK345). The EK transposase proteins increase the TnS transposition frequency 6-to 16-fold in cis and enhance the ability of transposase to act in trans. The purified mutant transposase proteins interact with transposon outside end DNA differently from the wild-type protein, resulting in the formation of a novel complex in gel retardation assays. During characterization of the transposase proteins in the absence of inhibitor, we found that wild-type transposase itself has a transposition-inhibiting function and that this inhibition is reduced for the mutant proteins. We present a model for the regulation of TnS transposition, which proposes the existence of two transposase species, one cis-activating and the other trans-inhibiting. The phenotype of the EK transposase mutants can be explained by a shift in the ratio of these two species.
Prokaryotic transposable elements can be viewed as existing in a symbiotic interaction with the bacterial host cell. The cell provides the environment necessary for replication and transposition of the element, and it benefits from the antibiotic resistance genes many transposons carry. Furthermore, a low level of random DNA rearrangements caused by transposition might help cells to adapt to environmental changes and increase the survival rate (23) . The transposition process, however, must be tightly regulated to prevent detrimental effects of an excessive level of DNA rearrangements.
TnS is a prokaryotic composite transposon consisting of two inverted insertion sequences, IS55R and IS5OL, flanking several antibiotic resistance genes (1) . Two features of Tn5 are essential for transposition: the peripheral 19 bp of the insertion sequences, called outside ends (16) , and the 476-amino-acid transposase protein (Tnp) encoded on IS55R (11) . The second IS55R protein, inhibitor (Inh), is expressed in the same reading frame as transposase but from independent transcriptional and translational start sites, resulting in a 421-amino-acid polypeptide lacking the first 55 residues of transposase (13) .
Tn5 transposition is controlled by a complex array of regulatory mechanisms, some inherent to the element and others involving host proteins. This regulation can be separated into three levels of control: limitation of transposase expression, regulation mediated by host proteins, and regulation of the transposase activity. Transposase expression is limited due to inefficient transcription initiation from a weak promoter (13) . The promoter activity is further reduced through DNA methylation by host-encoded Dam methylase (29) . As a consequence, the concentration of transposase in the cell is fourfold lower than the inhibitor protein concentration (12) . Transcripts initiated from spurious promoters outside the element cannot increase the level of transposase expression since these transcripts sequester the translational start site of transposase in a secondary structure and are not translated (22) . The host-encoded DnaA protein regulates transposition through direct contact with the transposon * Corresponding author.
DNA at specific binding sites (30) , perhaps resulting in the formation of a transposase-host protein-DNA complex. Integration host factor was found to affect Tn5 transposition (17) and might be involved in the formation of this complex. The regulatory mechanisms of other host proteins involved in transposition, GyrA (8) , PolA (20, 24) , LexA (26) , RecA (26) , and SulA (21) , are less well understood and may act through more indirect mechanisms.
Posttranslational regulation of the transposase activity is caused by the inhibitor protein (31) . Details of this inhibition remain unclear, but mounting evidence suggests that it is due to direct protein contact with transposase. The transposase protein seems to be able to form oligomers in vitro (4) , and evidence for the existence of transposase-inhibitor complexes in vivo was presented (5) . These observations led to the current hypothesis that Tn5 transposition is inhibited by the formation of inactive transposase-inhibitor heterooligomers. While the inhibitor protein inhibits transposition in trans, transposase is a cis-acting protein. It activates transposition efficiently only when expressed from the same replicon on which the outside end DNA sequences are located (12) . It is not understood what prevents transposase from diffusing to outside ends in trans to promote their transposition. The cis preference of transposase is apparently not caused by the interaction with the inhibitor protein (6) . A possible explanation for this phenomenon is that transposase is physically or functionally unstable and does not reach donor sites located on a different replicon.
In this paper, we describe the characterization of two transposase mutants that increase the Tn5 transposition frequency and partially overcome the transposase cis preference. On the basis of the observation that the transposase protein itself has an inhibiting function, we propose the existence of two transposase species, one that is cis activating and one which is trans inhibiting. The transposase cis preference may be due to rapid conversion of the activating protein into the inhibiting protein. The phenotype of the transposase mutants, i.e., increased transposition and higher trans activity, is consistent with a shift in the ratio of these two transposase species. (19) . Antibiotics were purchased from Sigma and used in the following concentrations: kanamycin, 40 Fig/ml; ampicillin, 100 ,ug/ml; tetracycline, 15 ,ug/ml; nalidixic acid, 20 ,ug/ml; gentamycin, 5 Strains, phage, and plasmids. All bacterial strains, phage, and plasmids used in this study are described in Table 1 . The structures of ISSOR carrying plasmids are shown in Fig. 1B . DNA manipulations were performed essentially as previously described (19 Sequencing of EK mutations. Subcloning of IS5OR fragments from mutagenized into unmutagenized pRZ620 localized the position of the hypertransposing mutations to a 748-bp PstI fragment for EK110 and a 519-bp NaeI-NheI fragment for EK345. These fragments were cloned into single-stranded DNA producing vectors pTZ18U and pTZ19U for DNA sequence analysis. By using the Sequenase kit (United States Biochemical Corp.) with slight modifications (22) , these fragments were sequenced entirely, and both mutations turned out to be single-base changes.
Transposition assays. The mating-out transposition assay was performed essentially as described previously (29) . The assay measures the movement of a transposable element from a plasmid to the F factor in the cell. After transfer of the F factor into recipient cells, the total number of exconjugants is compared with the number of exconjugants which received the transposon.
Ten microliters of donor RZ212-and 30 jl of recipient RZ221-saturated cultures were mixed with 1 ml of LB and incubated at 37°C in a roller drum shaker for 6 to 10 h. The cells were then diluted and plated on appropriate medium. Exconjugants were selected on LB agar plates containing 20 ,ug of nalidixic acid per ml and 5 ,ug of gentamycin per ml. Cells containing transposition products were identified on similar agar plates to which 40 ,ug of kanamycin per ml was added.
The bacteriophage X infection assay has been described previously (12) . The assay measures transposition of Tn5 from an infecting X phage to the chromosome of the host cell. X NK467 is conditionally defective for DNA replication and is unable to lysogenize the host. Recovery of the Tn5 kanamycin resistance, therefore, indicates a transposition event. Aliquots of stationary-phase cultures of MC1061 containing various plasmid derivatives of IS5OR were infected with X NK467 at a multiplicity of infection of 0.2. The mixture was incubated at 37°C for 15 min for phage absorption, LB medium was added, and incubation was continued for 30 min to allow the expression of kanamycin resistance. The cells were diluted and plated on LB plates with 40 jig of kanamycin per ml.
In both assays, dilutions were used that resulted in approximately 50 to 500 colonies per plate. Assays were performed in quintuplicate, and the standard deviations are indicated in the results (see Fig. 2 , 4, and 5). The variation within one set of assays was usually less than twofold.
Transposase purification. The purification of Tn5 transposase will be described in detail elsewhere (4) . In summary, transposase and the two EK mutant derivatives were overproduced in strain DH5a from pRZ7015, pRZ7015 EK110, and pRZ7015 EK345 by heat induction. Exponentially growing cultures were shifted from 32 to 42°C for 30 min, which causes denaturation of the bacteriophage X C1857 repressor and activates the X PR promoter. All following steps were performed at 4°C. One-liter batches of cells were harvested, resuspended in 0.1 M NaCl-TEG (20 mM Tris, 2 mM EDTA, 10% glycerol, 0.1% Triton X-100), and passed through a French pressure cell twice at 16,000 lb/in2. The supernatant from successive 26,000 x g and 100,000 x g spins was precipitated by addition of ammonium sulfate to 47% saturation. The pellets were resuspended in 0.4 M NaCl-TEG and dialyzed overnight. Crude transposase fractions were loaded onto a 10-ml heparin-agarose column and purified by elution with a 0.4 to 1.2 M NaCl gradient on a fast protein liquid chromatography system (Pharmacia LKB Biotechnology, Uppsala, Sweden). The protein peak fractions were adjusted to 20% glycerol-10 mM MgCl2 and quick frozen in liquid N2. A modified Bradford assay (2) was used to determine the protein concentrations, which were routinely about 0.5 mg/ml. Wild-type and mutant transposase species showed very similar purification profiles (data not shown).
Immunoblotting of IS50-encoded proteins. MC1061 cells carrying IS50R plasmids were grown in Luria broth with 100 jig of ampicillin per ml at 37°C to an A600 of approximately 0.5. The cells were pelleted and resuspended in protein gel loading buffer to contain 0.1 A600 equivalent of cells per 20 RIl (pRZ7013 and pRZ7016) or a 10-fold higher cell concentration (pRZ7024). The samples were incubated at 100°C for 5 min and sonicated for 30 s, and 20-Rl aliquots were loaded onto a 7% polyacrylamide gel. After electrophoretic separation, the proteins were electroblotted to nitrocellulose. The blot was incubated with rabbit antitransposase antibody and then with goat anti-rabbit immunoglobulin G-alkaline phosphatase conjugate. Antibody complexes were visualized with 5-bromo-4-chloro-3-indolylphosphate and nitroblue tetrazolium.
Gel retardation assay. A total of 0.5 to 2 jig (0.1 to 0.4 pmol) of purified transposase proteins was incubated with 1.5 ng (8 X 10-3 pmol) of 32P-labelled 266-bp fragment of DNA, containing the outside end of Tn5, in 20-jlI reactions at the final concentration of 20 mM P04 buffer (pH 7.5)-i mM dithiothreitol-0.5 mM EDTA-5% bovine serum albumin-100 mM potassium glutamate-0.1% Triton X-100-240-fold weight excess of unlabeled nonspecific competitor DNA. The reactions were incubated at 30°C for 30 min, glycerol was added to 4%, and 10-jil aliquots were analyzed by gel electrophoresis. Then, 1.2-mm-thick 5% (39:1) polyacrylamide gels were run in 0.5x Tris-borate-EDTA (TBE) at 8 W for 90 min at 4°C. Gel electrophoresis at room temperature resulted in a smearing of the retarded complexes (data not shown). Gels were dried, quantitated with a Betascope 603 blot analyzer (Betagen Corporation, Waltham, Mass.), and exposed to X-ray film overnight.
RESULTS
ISSOR EK mutations result in increased transposition frequencies. In order to screen for mutations in IS50R that increase transposition frequencies, the papillation assay (14) was used. In this transposition assay, TnS-mediated DNA rearrangements are visualized by the activation of a silent 3-galactosidase gene embedded in the transposon (TnS ORFlac). Eight hypertransposing IS50R mutants were isolated after diethyl sulfate mutagenesis of the papillation vector pRZ620 (Tn5 ORFlac on ColEl, Fig. 1B acids 110 (EK110) and 345 (EK345) of the transposase protein (Fig. 1A) .
Transposition frequencies of the mutants were determined by the mating-out assay in which transposition of TnS from a plasmid to the F factor is scored. Figure 2 shows that the transposition frequencies of both EK mutations are increased by about sixfold compared with those of the wild type. Throughout this study, the EK345 mutant consistently displays a stronger phenotype than does EK110, although the difference in transposition frequencies in this experiment falls within the observed error.
To address the question of whether the two mutations work independently of each other, we constructed the double mutant pRZ620 EK110/345. If the mutations act independently during transposition and no other step becomes rate limiting, the transposition frequency of the double mutant should be higher than the frequencies of the single mutants. Figure 2, We used site-directed mutagenesis to abolish expression of the inhibitor protein. The AUG start codon of inhibitorencoding methionine was changed to GCC, the codon for alanine. Unavoidably, this MA56 mutation also changes the amino acid sequence of transposase, substituting methionine with alanine at position 56 (Fig. 1A) .
To test whether MA56 constructs indeed fail to express the inhibitor protein, we used immunoblotting analysis with antibodies that were raised against transposase and crossreact with the inhibitor. Figure 3 shows a Western blot (immunoblot) of IS5OR proteins expressed from high-copynumber plasmids with the wild-type inhibitor start codon (lane 3) or the MA56 mutation (lane 4). Comparison of lanes 3 and 4 confirms that no inhibitor is expressed from MA56 constructs and that transposase stability is not affected by the missense mutation. Lane 5 contains ISSOR proteins expressed from a medium-copy-number plasmid and was loaded with a 10-fold higher concentration of cells. This lane indicates that the amounts of transposase and inhibitor in the cell are dependent on the copy number of the IS5OR plasmid (see below). The shift in the ratio of transposase to inhibitor could be due to a lower methylation state of the high-copy-number plasmid which would favor transposase expression.
To compare transposition frequencies in the presence and absence of inhibitor for wild-type and EK mutant transposase proteins, we constructed two sets of plasmids. The plasmids contain wild-type TnS or the EK derivatives cloned onto a high-copy-number vector. One set of plasmids carries the wild-type inhibitor start codon (pRZ7017), whereas the other set contains the MA56 mutation (pRZ7018).
The MA56 mutation by itself causes a 10-fold increase in TnS transposition (Fig. 4, columns 1 measured in the presence of inhibitor (Fig. 4, columns 2 and  3 ). These transposition increases are greater than those observed for Fig. 2 , presumably due to the higher copy number of the transposon carrying plasmids in this experiment (see Discussion). The corresponding MA56/EK double mutants show increases of six-and sevenfold over the MA56 construct (Fig. 4, column 4 versus columns 5 and 6), so most of the effect of the EK mutations is not dependent on the presence of the inhibitor protein. We conclude that the presence of the inhibitor protein is not necessary for the hypertransposing phenotype. It must, therefore, be due to the alteration in the transposase protein.
Activities of transposase EK mutations are increased in trans. Transposase activates transposition to a greater extent when the protein is expressed on the same replicon that contains the transposon ends (cis complementation) compared with activating transposition of an element on a separate replicon (trans complementation). After the observation that the EK mutations increase the transposition frequency in cis, we wanted to test whether this increase is also manifested in a trans-complementing situation.
To test this trans activity, transposase was expressed from IS5OR on a high-copy plasmid, pRZ7016. All of the ISSOR constructs in this experiment carry the MA56 mutation, allowing only transposase and not inhibitor expression, which simplifies the interpretation of the results. Transposition was scored as the movement of a kanamycin resistance gene flanked by two TnS outside ends from a second, compatible plasmid (pRZ4711) to the F factor of the host cell. This reporter Tn5 element does not encode transposase or inhibitor. Figure 5 shows the results of this trans-activity assay. As expected, the level of transposition promoted in trans is about 20-fold lower than that in cis (compare Fig. 4 , column 4, with Fig. 5, column 1 Transposase is expressed from pRZ7016 (IS5OR MA56 on pBKS-) and trans-activates transposition of a reporter element from a second compatible plasmid, pRZ4711 (outside ends flanking a kanamycin resistance gene on pACYC184), to the F factor. The transposase-expressing plasmids contain the MA56 mutation to prevent inhibitor expression from interfering with the assay and were (from left to right) pRZ7016, pRZ7016 EK110, and pRZ7016 EK345. At the bottom of the figure is a list of the relative increases in transposition for the EK mutations and the trans activities of the transposase proteins compared with their corresponding cis activities (Fig. 4 , columns 4 to 6). Trans activity is calculated as the ratio of transposition frequency in trans to the frequency in cis times 100 and is expressed in percent.
transposition to frequencies determined in trans is listed as the trans activity for each transposase protein. Note that the trans activities for the EK110 and EK345 mutants are 8.8 and 9.5% of their respective cis activities compared with 4.6% for the control transposase. Therefore, the mutations increase transposition in trans, and the relative increase is even larger than that in cis. These increased trans activities of the EK transposase mutants, although consistently observed in additional assays, vary between 8 and 30% of the respective cis activities. The reason for this variability is not known.
Binding of EK mutant transposase proteins to outside end DNA reveals a novel retarded complex. The fact that we observed a greater transposition increase in trans than in cis led us to believe that the EK mutations affect an early step in the transposition process, perhaps enhancing the affinity of transposase for the outside ends. Once the predicted complex of transposase and the transposon end DNA is formed, cis and trans complementation of transposition should become indistinguishable. Therefore, we wanted to compare the specific binding of wild-type and EK mutant transposase proteins with the outside end DNA of TnS.
The EK mutations were cloned onto a transposase-overproducing plasmid, pRZ7015. In this construct, transposase is under the control of the bacteriophage X P, promoter, which can be activated by denaturation of the temperaturesensitive X CI 857 protein at 42°C. After overexpression, wild-type and mutant transposase proteins were purified by heparin-agarose column chromatography (4) . A Coomassiestained polyacrylamide gel of the purified proteins shows that transposase represents approximately 80% of the total protein (Fig. 6) . The remaining species are contaminating inhibitor and Tnp-cx, a proteolytic cleavage product of transposase (3) .
Increasing amounts of purified transposase were incubated with end-labeled DNA containing the outside end of Tn5, and the reactions were then separated on a nondenaturing polyacrylamide gel. Figure 7A shows that transposase forms specific complexes with the outside end DNA. Transposase as inhibitor of Tn5 transposition. After constructing the MA56 mutation, we showed that the replacement of the inhibitor start codon resulted in the physical absence of the protein on a,Western blot (see above). A second assay was then performed to confirm the functional absence of an inhibiting factor. We chose the bacteriophage X infection assay, which was originally used to identify the function of the inhibitor protein (12) .
Cells were infected with TnS inserted into a genetically defective bacteriophage X vector (A NK467) which can neither replicate nor integrate into the host chromosome. The infecting A TnS DNA is undermethylated, a condition which allows very little inhibitor protein expression and results in an initial burst of transposase production (18) . Transposition events driven by this transposase were scored as the recovery of kanamycin-r9sistant host cells after infection. However, when a plasmid expressing inhibitor protein at a steady-state level is present in the cell, TnS transposition from the A phage is greatly reduced (12) . To test the effect of different levels of TnS proteins, we used both medium-and high-copy-number plasmids (see Fig. 3 ). Transposition frequencies in cells carrying plasmids with the following features were compared: vectors containing IS50 end sequences but expressing no TnS proteins as a negative control (pRZ7039 and pRZ7038), vectors containing ISSOR expressing both transposase and inhibitor (pRZ7024 and pRZ7013), and vectors containing IS5OR MA56 expressing only transposase (pRZ7029 and pRZ7016).
As expected, transposition decreases about 50-fold when both transposase and inhibitor are expressed at steady-state levels from a medium-copy-number plasmid (Fig. 8A , columns 1 and 2). Since transposase is mainly cis acting, its expression from the plasmid should not significantly activate transposition of the A TnS element and, therefore, not interfere with the assay.
To our surprise, we found that transposition is decreased, even in the absence of the inhibitor protein. When transposase, but not inhibitor, is expressed from the plasmid, transposition is threefold lower than that in control cells not containing TnS proteins (compare Fig. 8A column 5 and column 1). This result is more pronounced when the TnS proteins are present at higher concentrations by expression from high-copy-number plasmids. Transposition in the presence of a higher steady-state level of transposase reaches only 3% of the frequency measured for the control cells (Fig. 8B, columns 5 and 1) . We interpret this phenomenon as evidence that TnS transposase has two functions: activation of transposition in cis and inhibition of transposition in trans.
We then tested the EK transposase mutants for this inhibitory effect and observed approximately twofold higher transposition frequencies, and, therefore, lower inhibition, than measured with the corresponding wild-type proteins.
The transposition increase was observed both with the absence of inhibitor protein (Fig. 8, columns 6 and 7) and when inhibitor and transposase were expressed in steadystate levels (Fig. 8, columns 3 and 4) . This indicates that the EK mutations reduce the inhibitory effect of transposase, although we have not ruled out that this result might be partially due to the increased trans activity of the mutant transposase proteins.
DISCUSSION
This study independently confirms the recent finding that Tn5 transposase is not only a cis-acting activator of the transposition process but also a trans-active inhibitor (6) . This observation uncovers yet another layer of regulation to modulate the frequency of TnS transposition. Transposable elements need to prevent uncontrolled transposition, which would be detrimental for the host cell and, in turn, for the transposon itself.
One regulatory mechanism to control TnS transposition is the limitation of transposase expression (13) . An additional level of control is the regulation of transposase activity by the inhibitor protein. This protein is missing critical amino acids required for transposition activation but retains enough similarity to transposase to be involved in, and thereby interfere with, the transposition reaction.
This (3) , which argues against the first mechanism. Favoring the second possibility are the following considerations. We expect that transposase contains a multimerization site. Oligomerization during the transposition process would allow the interaction of the transposon ends (9) . Indeed, transposase elutes as an apparent tetramer when it is passed through a gel exclusion column (4) . Since the inhibitor protein consists of the carboxy-terminal 9/10th of the transposase, it seems reasonable that the oligomerization site is shared by these two proteins. Furthermore, indirect evidence that inhibitor contacts transposase in vivo was presented (5) . In Fig. 9 , we present a model of transposition regulation which is consistent with the observed data. We postulate the existence of two different transposase species: active transposase capable of promoting transposition and inactive transposase which has inhibitory function. The active transposase oligomerizes, interacts with the transposon ends, and carries out the reactions necessary for transposition. The inhibitor binds to the active transposase monomers and forms inactive hetero-oligomers. This diminishes the concentration of the active species and thereby reduces the frequency of transposition. The inactive transposase species exerts its inhibitory effect in the same fashion.
The existence of two transposition-inhibiting protein species may explain why we observe only a limited increase of the transposition frequency in the absence of the inhibitor protein (Fig. 4) . The model predicts that both inhibitor and inhibiting transposase need to be absent to allow a further increase. However, we have not ruled out the possibility that the alanine missense mutation in transposase results in decreased activity or that host factors become rate limiting for the transposition reaction.
The model leaves open whether initially inactive transposase is made, which needs to be activated, or whether active transposase is the first product, which subsequently is inactivated. We favor the second possibility since it would explain why transposase is cis activating but trans inhibiting, i.e., by the time newly translated transposase reaches Tn5 end sequences on a second replicon, most of the transposase would be inactivated.
This inactivation step could be due to a wide array of transposase alterations, and it may or may not be dependent on host factors. Transposase could, for example, be phosphorylated or dephosphorylated, undergo a conformational change, or be proteolytically cleaved. We routinely observe a transposase degradation product, Tnp-cL, in purified transposase preparations (Fig. 6) . Preliminary experiments indicate that Tnp-ot is caused by cleavage in the N-terminal 55 residues specific to transposase (3) . We are testing the possibility that Tnp-ot is the inhibiting transposase species.
The presented model also provides an explanation for the phenomenon that the frequency of Tn5 transposition in the cell is fairly independent of the copy number of the plasmid on which the transposon is located (10 Fig. 8  and 9 , is more pronounced when the IS5OR proteins are expressed from a high-copy-number plasmid.
How does the proposed model of transposition regulation explain the phenotype of the EK mutations? One possibility that fits the observations is that the EK mutations shift the ratio of activating versus inhibiting transposase, for example, by delaying the inactivation process. This would result not only in the observed increase in transposition frequency but also in a greater increase in trans, since the active transposase has more time to reach transposon DNA end sequences located on a different replicon.
We, furthermore, observed that the EK mutations show a greater transposition increase when they are present on a high-copy-number plasmid (compare Fig. 2 and 4) . This is the expected result since the EK mutations would partially overcome the above-mentioned copy number effect.
The fact that the inhibition assay (Fig. 8) shows only a modest restoration of transposition frequencies for the EK mutations might be due to the specific design of the assay, in which we are providing wild-type transposase in cis on the X phage. Therefore, we are observing only the effect of the decrease in inhibiting EK mutant transposase rather than the coupled increase in active and decrease in inhibiting transposase species. The higher transposition frequencies of the EK mutants in this assay, however, could also reflect the increased ability of the plasmid-encoded mutant transposase proteins to activate transposition of the X TnS element in trans.
Assuming a changed ratio of active to inactive EK mutant transposase, the gel retardation patterns can be interpreted in the following way. The upper retarded band (Fig. 7A , complex I), which is slightly weaker for the EK mutants, results from a nonproductive interaction of active and inactive transposase hetero-oligomers with the TnS end sequences. The lower retarded band (complex II), appearing only faintly for the wild type and much stronger for the EK mutants, represents the DNA interaction with an active transposase complex. This interpretation is consistent with the observed correlation of the intensity of complex II with the genetically determined transposition frequency.
The altered migration of complex II could be due directly to the difference between the active and inactive transposase molecules: a change in protein conformation or molecular weight, for example. However, several other molecular explanations are possible. If DNA is bent after binding to transposase, then the two complexes could differ in the angle of this bend. Or complex II could contain a transposaseinduced nick in the DNA. Finally, complex I could contain more transposase molecules than complex II. We are currently testing these possibilities. Investigating the DNAbinding characteristics of the EK mutant transposase proteins could help to elucidate the early steps of the transposition process.
Finally, we are using the purified hyper-trans-active EK mutant transposase proteins to develop an in vitro assay for TnS transposition. This assay is critical for a biochemical analysis of the molecular mechanism of the transposition reaction. To observe transposition in vitro, transposase protein will be added to outside end DNA sequences and the reaction will be tested for the formation of transposition products. We expect to see initially a very low signal, since trans-activated TnS transposition occurs extremely infrequently in vivo. The hyper-trans-active character of the EK mutant transposase proteins, however, will increase our chances for the successful development of the TnS in vitro transposition assay.
